Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Varada Nargund

Interventional Pain Medicine Glen Burnie, MD Doctor of Osteopathy

NPI 1417032277 CMS profile 18860

1600 Crain Hwy S, Suite 301, Glen Burnie, MD 21061

Open in the dashboard

General payments

$7,250

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Varada Nargund of Glen Burnie, MD is reported in the CMS Open Payments database as having received $7,250 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $865 28
2024 General $1,002 24
2023 General $1,668 71
2022 General $1,349 73
2021 General $1,139 65
2020 General $609 31
2019 General $617 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Varada Nargund
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Varada Nargund were reported at $865. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Varada Nargund Interventional Pain Medicine median Middle half National median
2019 $617 $684 $216–$2,079 $163
2020 $609 $382 $122–$1,109 $114
2021 $1,139 $552 $167–$1,554 $132
2022 $1,349 $605 $187–$1,924 $149
2023 $1,668 $671 $195–$1,915 $160
2024 $1,002 $684 $206–$1,837 $164
2025 $865 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,514 49 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $704 80 payments
  3. BIOTRONIK NRO, Inc. $643 12 payments
  4. Vertos Medical, Inc. $459 13 payments
  5. Medtronic, Inc. $364 9 payments
  6. Abbott Laboratories $333 12 payments
  7. Nevro Corp. $281 10 payments
  8. Collegium Pharmaceutical, Inc. $241 17 payments
  9. Flexion Therapeutics, Inc. $232 8 payments
  10. Spinal Simplicity, LLC $220 6 payments
  11. Other $2,259 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,250 324 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $759 27 payments
  2. RELISTOR $728 82 payments
  3. mild Device Kit $459 13 payments
  4. Prospera Not Applicable $337 5 payments
  5. INTELLIS ADAPTIVESTIM $260 7 payments
  6. Zilretta $232 8 payments
  7. XTAMPZA $224 16 payments
  8. HA MINUTEMAN G3-R $220 6 payments
  9. Prospera Not Applicable $209 4 payments
  10. Infinion 16 $206 2 payments
  11. Other $4,383 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

349

Median for Interventional Pain Management: 1,220

Drug cost

$4,262

Median for Interventional Pain Management: $39,344

Branded share of claims

14.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 137 $2,469
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 25 $525
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $339
Clindamycin Hcl Generic 69 $316
Cyclobenzaprine Hcl Generic 17 $195
Gabapentin Generic 19 $155
Pregabalin Generic 12 $111
Tizanidine Hcl Generic 16 $101
Tramadol Hcl Generic 27 $51

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$358,990

Medicare's payments for the services billed

Medicare patients

350

Average age 72

Services billed

2,096

240 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 39%
Diabetes 34%
Ischemic heart disease 28%
Chronic kidney disease 26%
COPD 20%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record